Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Click to view quick news summary (Spoiler)
Evaxion is set to reveal key preclinical data for its multi-component CMV vaccine, EVX-V1, at the IHW 2026. Utilizing the AI-Immunology™ platform, the vaccine combines novel antigens with AI-optimized glycoproteins to fight the widespread cytomegalovirus.
Evaxion, a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new preclinical data for vaccine candidate EVX-V1 in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15, 2026.
EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens.The new preclinical data will guide final antigen selection for a broadly protective CMV vaccine candidate as we progress the program according to plan.
About EVX-V1 and AI-Immunology
EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens.Through this combination, EVX-V1 attacks the virus from multiple, complementary angles.This broader multi-targeted strategy is expected to strengthen the protective potential of the vaccine.
With our AI-Immunology™ platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field.These previously unexplored CMV-antigens induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal viral infection models.EVX-V1 is a combination of these antigens with our proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen which has demonstrated superior performance compared to the traditional gB antigen, including enhanced CMV neutralization.
The Burden of CMV
About 1 in 200 babies is born with congenital CMV infection.About 1 in 5 babies with the infection will have congenital disabilities or other long-term health problems.CMV infects approximately 60% to 70% of adults in developed countries and nearly 100% in developing economies, driving demand for CMV treatment.Despite decades of research, no CMV vaccine has been approved to date.
CMV treatment market size was valued at $474.6 million in 2023 and is anticipated to register an annual growth (CAGR) of 6.6% between 2024 and 2032. This growth is propelled by increasing awareness and prevalence of CMV infection and the development of new and effective treatments.CMV is the most complex of all herpes viruses and is a widespread infection transmitted in body fluids.Once infected, the virus stays for life. People with weakened immune systems, including organ transplant patients, can develop severe symptoms affecting, for example, eyes, lungs, and liver, and congenitally infected babies may suffer from intellectual disability and loss of vision and hearing.
About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™.The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development.Our team of +40 experts covers the entire value chain from target discovery to clinical development.We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases.All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
